CU23157A1 - COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL - Google Patents

COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL

Info

Publication number
CU23157A1
CU23157A1 CU20010005A CU20010005A CU23157A1 CU 23157 A1 CU23157 A1 CU 23157A1 CU 20010005 A CU20010005 A CU 20010005A CU 20010005 A CU20010005 A CU 20010005A CU 23157 A1 CU23157 A1 CU 23157A1
Authority
CU
Cuba
Prior art keywords
pharmaceutical composition
lack
composition
organs
prophylactic
Prior art date
Application number
CU20010005A
Other languages
English (en)
Inventor
Acosta Jorge Berlanga
Alba Jose Suarez
Perez Isabel Guillen
Garcia Mario Pablo Estrada
Del Barco Herrera Diana Garcia
Nieto Gerardo Enrique Guillen
Rodriguez Rebeca Martinez
Masso Julio Raul Fernandez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20010005A priority Critical patent/CU23157A1/es
Priority to SI200130436T priority patent/SI1354597T1/sl
Priority to CA2398983A priority patent/CA2398983C/en
Priority to AT01272599T priority patent/ATE302017T1/de
Priority to DE60112807T priority patent/DE60112807T2/de
Priority to EA200500646A priority patent/EA007466B1/ru
Priority to ES01272599T priority patent/ES2248229T3/es
Priority to EA200200850A priority patent/EA006036B1/ru
Priority to DK01272599T priority patent/DK1354597T3/da
Priority to AU2002216897A priority patent/AU2002216897A1/en
Priority to PCT/CU2001/000013 priority patent/WO2002053167A2/es
Priority to JP2002554116A priority patent/JP4181875B2/ja
Priority to US10/220,750 priority patent/US7361638B2/en
Priority to EP01272599A priority patent/EP1354597B1/en
Priority to MXPA02008667A priority patent/MXPA02008667A/es
Priority to CA 2789161 priority patent/CA2789161C/en
Priority to KR1020027011276A priority patent/KR100839857B1/ko
Priority to CNB018059783A priority patent/CN1247256C/zh
Priority to BRPI0108882A priority patent/BRPI0108882B8/pt
Priority to MYPI20015758A priority patent/MY129079A/en
Priority to ARP010106097A priority patent/AR032217A1/es
Priority to ZA200206954A priority patent/ZA200206954B/en
Priority to HK03105815A priority patent/HK1053428A1/xx
Publication of CU23157A1 publication Critical patent/CU23157A1/es
Priority to JP2008141792A priority patent/JP4958844B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invencion se relaciona con la medicina humana y en particular con una composicion farmacÉutica que comprende el Factor de Crecimiento EpidÉrmico (EGF) y un pÉptido mimÉtico del factor de liberacion de la hormona de crecimiento (GHRP), la cual es Util en la prevencion y/o restauracion del dano tisular que se provoca por falta de irrigacion sanguínea a un organo determinado debido a diferentes condiciones patologicas. La composicion puede aplicarse a un individuo como parte de un tratamiento mÉdico, profilActico o terapÉutico, que favorece la vitalidad celular en organos cuando estos son sometidos a privacion parcial o totalmente del suministro de sangre oxigenada durante un período de tiempo. Esta composicion tambiÉn atenUa la formacion de especies y metabolitos toxicos en dichos oragnos, por lo que es particularmente Util en tejidos sometidos a prolongados períodos de isquemia. La composicion farmacÉutica puede ser aplicada ademAs con carActer profilActico en sujetos con entidades que pueden conducir a la disfucion o dano mUltiple de organos de diverso origen como quemados, politraumatizados, síndrome de distress respiratorio, neonatos hipoxicos, shock hipovolÉmico, enterocolitis necrotizante, así como a sujetos sometidos a grandes intervenciones quirUgicas.
CU20010005A 2001-01-03 2001-01-03 COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL CU23157A1 (es)

Priority Applications (24)

Application Number Priority Date Filing Date Title
CU20010005A CU23157A1 (es) 2001-01-03 2001-01-03 COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP2002554116A JP4181875B2 (ja) 2001-01-03 2001-12-17 動脈血流不足による組織損傷処置用医薬組合せ
CNB018059783A CN1247256C (zh) 2001-01-03 2001-12-17 用于治疗动脉血流衰竭所致组织损伤的药物组合物
AT01272599T ATE302017T1 (de) 2001-01-03 2001-12-17 Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
DE60112807T DE60112807T2 (de) 2001-01-03 2001-12-17 Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
EA200500646A EA007466B1 (ru) 2001-01-03 2001-12-17 Фармацевтическая композиция для лечения повреждения тканей, вызванного недостаточностью артериального кровотока
ES01272599T ES2248229T3 (es) 2001-01-03 2001-12-17 Combinacion farmaceutica para el tratamiento de daños en tejidos debidos a defectos de irrigacion arterial.
EA200200850A EA006036B1 (ru) 2001-01-03 2001-12-17 Фармацевтическая комбинация для профилактики и лечения повреждений, связанных с дефицитом артериального кровотока
DK01272599T DK1354597T3 (da) 2001-01-03 2001-12-17 Farmaceutisk kombination til behandling af vævsskader forårsaget af en arterieirrigationsdefekt
AU2002216897A AU2002216897A1 (en) 2001-01-03 2001-12-17 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
PCT/CU2001/000013 WO2002053167A2 (es) 2001-01-03 2001-12-17 Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial
SI200130436T SI1354597T1 (sl) 2001-01-03 2001-12-17 Farmacevtska kombinacija za zdravljenje tkivne poskodbe zaradi arterijskega irigacijskega defekta
US10/220,750 US7361638B2 (en) 2001-01-03 2001-12-17 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
CA 2789161 CA2789161C (en) 2001-01-03 2001-12-17 Pharmaceutical composition to prevent tissue damage due to arterial blood flow failure
MXPA02008667A MXPA02008667A (es) 2001-01-03 2001-12-17 Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial.
EP01272599A EP1354597B1 (en) 2001-01-03 2001-12-17 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
KR1020027011276A KR100839857B1 (ko) 2001-01-03 2001-12-17 동맥혈의 전달이상으로 인한 조직손상 치료용 약제학적조합
CA2398983A CA2398983C (en) 2001-01-03 2001-12-17 Pharmaceutical composition to prevent tissue damage due to arterial blood flow failure
BRPI0108882A BRPI0108882B8 (pt) 2001-01-03 2001-12-17 combinação farmacêutica
MYPI20015758A MY129079A (en) 2001-01-03 2001-12-19 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
ARP010106097A AR032217A1 (es) 2001-01-03 2001-12-28 Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial
ZA200206954A ZA200206954B (en) 2001-01-03 2002-08-29 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect.
HK03105815A HK1053428A1 (en) 2001-01-03 2003-08-14 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
JP2008141792A JP4958844B2 (ja) 2001-01-03 2008-05-30 動脈血流不足による組織損傷処置用医薬組合せ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010005A CU23157A1 (es) 2001-01-03 2001-01-03 COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL

Publications (1)

Publication Number Publication Date
CU23157A1 true CU23157A1 (es) 2006-07-18

Family

ID=40091523

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20010005A CU23157A1 (es) 2001-01-03 2001-01-03 COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL

Country Status (21)

Country Link
US (1) US7361638B2 (es)
EP (1) EP1354597B1 (es)
JP (2) JP4181875B2 (es)
KR (1) KR100839857B1 (es)
CN (1) CN1247256C (es)
AR (1) AR032217A1 (es)
AT (1) ATE302017T1 (es)
AU (1) AU2002216897A1 (es)
BR (1) BRPI0108882B8 (es)
CA (2) CA2398983C (es)
CU (1) CU23157A1 (es)
DE (1) DE60112807T2 (es)
DK (1) DK1354597T3 (es)
EA (2) EA007466B1 (es)
ES (1) ES2248229T3 (es)
HK (1) HK1053428A1 (es)
MX (1) MXPA02008667A (es)
MY (1) MY129079A (es)
SI (1) SI1354597T1 (es)
WO (1) WO2002053167A2 (es)
ZA (1) ZA200206954B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
WO2005042003A1 (en) * 2003-10-24 2005-05-12 Merck & Co., Inc. Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
US20070254837A1 (en) * 2003-12-16 2007-11-01 University Technologies International Inc. Treatment for Necrotizing Enterocolitis
CU23529A1 (es) * 2005-03-02 2010-06-17 Ct Ingenieria Genetica Biotech Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CU23389B6 (es) * 2005-12-29 2009-07-16 Ct Ingenieria Genetica Biotech Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica
CU23592A1 (es) * 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
CU23526B6 (es) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
WO2008134635A1 (en) * 2007-04-30 2008-11-06 Nationwide Children's Hospital Heparin binding epidermal growth factor (hb-egf) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
JP5797112B2 (ja) 2008-07-17 2015-10-21 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20170001567A (ko) 2015-06-26 2017-01-04 주식회사 파마리서치프로덕트 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
US11197944B2 (en) 2015-11-18 2021-12-14 President And Fellows Of Harvard College Compositions and methods of mechanically inducing tissue regeneration
CA3110173A1 (en) 2018-08-21 2020-02-27 Centro De Ingenieria Genetica Y Biotecnologia Use of ghrp-6 as late cardioprotective and cardiac restoration medicament
CU24591B1 (es) * 2018-08-21 2022-04-07 Ct Ingenieria Genetica Biotecnologia Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento
CN109908331A (zh) * 2019-04-30 2019-06-21 青岛大学附属医院 海沙瑞林在制备保护肾脏缺血再灌注损伤药物/药物组合物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5360790A (en) * 1990-12-11 1994-11-01 The Regents Of The University Of Michigan Method and formulations for the therapy of acute renal failure
KR970032600A (ko) 1995-12-30 1997-07-22 배순훈 전기압력보온밥솥용 압력센싱장치의 이상 발생인식방법
SE9703929D0 (sv) 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method
KR100226985B1 (ko) * 1997-07-14 1999-10-15 윤재승 신규한 인간성장호르몬방출인자-인간상피세포성장인자 융합유전자, 이의 발현벡터 및 이를 이용한 인간성장호르몬방출인자의 제조방법
US6191109B1 (en) * 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
WO2000012047A2 (en) * 1998-09-02 2000-03-09 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
JP2004507456A (ja) * 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
US20020061838A1 (en) 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
IL153067A0 (en) * 2000-06-13 2003-06-24 Zentaris Ag Growth hormone secretagogues

Also Published As

Publication number Publication date
EA007466B1 (ru) 2006-10-27
MXPA02008667A (es) 2003-03-27
EP1354597B1 (en) 2005-08-17
MY129079A (en) 2007-03-30
KR100839857B1 (ko) 2008-06-19
WO2002053167A3 (es) 2002-11-14
ATE302017T1 (de) 2005-09-15
EA006036B1 (ru) 2005-08-25
CN1247256C (zh) 2006-03-29
US20030186865A1 (en) 2003-10-02
EP1354597A2 (en) 2003-10-22
AU2002216897A1 (en) 2002-07-16
AR032217A1 (es) 2003-10-29
ZA200206954B (en) 2003-12-01
SI1354597T1 (sl) 2006-02-28
CA2789161C (en) 2015-04-07
CA2398983A1 (en) 2002-07-11
JP4181875B2 (ja) 2008-11-19
JP2008231121A (ja) 2008-10-02
BR0108882A (pt) 2003-04-29
ES2248229T3 (es) 2006-03-16
JP4958844B2 (ja) 2012-06-20
BRPI0108882B1 (pt) 2016-06-14
DE60112807T2 (de) 2006-06-29
JP2004516332A (ja) 2004-06-03
CN1407899A (zh) 2003-04-02
DE60112807D1 (de) 2005-09-22
WO2002053167A2 (es) 2002-07-11
US7361638B2 (en) 2008-04-22
CA2789161A1 (en) 2002-07-11
HK1053428A1 (en) 2003-10-24
EA200500646A1 (ru) 2005-10-27
DK1354597T3 (da) 2005-12-19
KR20030001370A (ko) 2003-01-06
EA200200850A1 (ru) 2003-02-27
BRPI0108882B8 (pt) 2021-05-25
CA2398983C (en) 2012-11-20

Similar Documents

Publication Publication Date Title
CU23157A1 (es) COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
Mitsimponas et al. The free scapular/parascapular flap as a reliable method of reconstruction in the head and neck region: a retrospective analysis of 130 reconstructions performed over a period of 5 years in a single department
CR8828A (es) Derivados de metastina y utilizacion de los mismos
US20230285449A1 (en) Photosynthetic cellular substances and methods of use thereof
EA200900881A1 (ru) Ингаляционные лекарственные формы связанных с полимерами бифосфонатов и способы их применения
Gehmert et al. Evaluation of hyperbaric oxygen therapy for free flaps using planar optical oxygen sensors. Preliminary results
Elyassi et al. Closure of difficult palatal fistulas using a “parachuting and anchoring” technique with the tongue flap
IL181286A0 (en) Methods of healing wounds by administering human il-18
EA202190798A1 (ru) Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов
RU2420242C1 (ru) Способ хирургического лечения седловидной деформации спинки носа
Kessler et al. Feasibility of an endoscopic approach to the submandibular neck region—experimental and clinical results
Lord The relation of the pneumococcus to the production of acid in fluid culture mediums and the reaction of the pneumonic lung
Putra et al. EARLY MANAGEMENT AND WOUND DRESSING SELECTION FOR CERVICAL NECROTIZING FASCIITIS: A CASE REPORT
Moghari et al. The use of split metatarsal osteocutaneous free flaps in palatal and alveolar defects
RU2590862C1 (ru) Способ реконструкции языка после его половинной резекции
Iorio et al. Use of Integra, a bilayered human skin equivalent, in the treatment of diabetic foot ulcers
Lodhi et al. Total thyroidectomy in Benign multinodular goitre
RU2485911C1 (ru) Способ протезирования больных с выраженными врожденными аномалиями развития и приобретенными деформациями альвеолярных гребней костей верхней и нижней челюстей
PL425351A1 (pl) Kompozycja zawierająca peptyd IM, zestaw oraz zastosowanie do pobudzania regeneracji tkanki złożonej lub leczenia ran
Williams Oxygenation in Radiotherapy of Malignant Disease of the Upper Air Passages [Abridged] The Effect of Intra-Arterial Hydrogen Peroxide
CN108066138A (zh) 高压氧舱内肢体局部吸氧套桶及其应用
Froum Hyperbaric oxygen therapy in the dental field
Westlake ON POINTS OF IMPORTANCE CONNECTED WITH THE TREATMENT OF ULCERATED LEGS.
Dawson et al. Shortness of breath
DE50310383D1 (de) Humanes chondroosteomodulin (tig2), herstellung und verwendung zur behandlung oder diagnose von knochen- und knorpelerkrankungen, fettsucht sowie entzündlichen erkrankungen und hauterkrankungen